Valeant Chief Executive Officer Mike Pearson To Give Deposition To Senate Committee Investigating Drug Pricing

Michael "Mike" Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International Inc., exits a a Senate Committee on Rules and Administration office in Washington, D.C., U.S., on Monday, April 18, 2016. The committee is deposing Pearson in private before an April 27 hearing in Washington where he is scheduled to testify. Pearson had originally failed to comply with a subpoena to be deposed and changed course after the committee threatened to hold him in contempt. Photographer: Drew Angerer/Bloomberg via Getty Images
Michael "Mike" Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International Inc., exits a a Senate Committee on Rules and Administration office in Washington, D.C., U.S., on Monday, April 18, 2016. The committee is deposing Pearson in private before an April 27 hearing in Washington where he is scheduled to testify. Pearson had originally failed to comply with a subpoena to be deposed and changed course after the committee threatened to hold him in contempt. Photographer: Drew Angerer/Bloomberg via Getty Images
Valeant Chief Executive Officer Mike Pearson To Give Deposition To Senate Committee Investigating Drug Pricing
PURCHASE A LICENSE
How can I use this image?
kr 4,000.00
NOK

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:
Bloomberg / Contributor
Editorial #:
522340084
Collection:
Bloomberg
Date created:
April 18, 2016
Upload date:
License type:
Release info:
Not released. More information
Source:
Bloomberg
Object name:
PEARSON VALEANT
Max file size:
4355 x 2903 px (14.52 x 9.68 in) - 300 dpi - 5 MB